Study of SND14 for mild dementia

Trial Profile

Study of SND14 for mild dementia

Phase of Trial: Phase II/III

Latest Information Update: 19 Apr 2017

At a glance

  • Drugs Sodium benzoate (Primary)
  • Indications Dementia
  • Focus Therapeutic Use
  • Most Recent Events

    • 19 Apr 2017 New trial record
    • 04 Apr 2017 According to a SyneuRx International (Taiwan) corp media release, the company has announced that the U.S. FDA has approved their newest IND program for SND14 as a treatment for mild dementia.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top